On the morning of March 7th, Dr. Beate Mueller-Tiemann, the Global Chief Technology Officer of Cytiva (a well-known global company in the life sciences field), and her delegation visited the National Facility for Translational Medicine (Sichuan) at West China Hospital (WCH) to discuss and exchange ideas on research cooperation in the field of cell and gene therapy. Vice President Chen Lei attended the meeting, along with representatives and experts from WCH’s Research Laboratory Management Department, Clinical Research Management Department, Thoracic Oncology Ward, CTC Center, and Western China Medical Technology Transfer Center.

 

At the meeting, Vice President Chen Lei extended a sincere welcome to the Cytiva delegation. She expressed her hope that the company would leverage its international business strengths in cell and gene therapy, and in combination with the specific needs of WCH’s platform and scientists, plan a blueprint for cooperation in the field of cell and gene therapy and implement it step by step in phases. Dr. Beate Mueller-Tiemann and Mr. Li Lei, the President of Cytiva China, respectively introduced the company’s strengths and key business areas.

 

In the future, both parties will enhance communication and mutual promotion, and explore a mature path for the full innovation chain of WCH’s cell and gene therapy projects, from basic research to clinical translation and then to drug marketing. This will provide our scientists with excellent full-chain solutions and improve the clinical translation efficiency of our hospital’s cell and gene-related projects.